MIT-Harvard Center of Cancer Nanotechnology Excellence

麻省理工学院-哈佛大学癌症纳米技术卓越中心

• 批准号: 8136182
• 负责人: ROBERT Samuel LANGER
• 金额: $ 229万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8136182
• 关键词: MIT; Harvard; Center; Cancer; Nanotechnology

The overall goal of this U54 application is to support a highly multidisciplinary team of expert chemists, engineers, biologists, material scientists and clinicians to develop and rapidly translate new nanotechnologies to better diagnose and treat cancer in the clinic. This team formed a Center for Cancer Nanotechnology Excellence (CCNE) in 2004 and over the past 5 years has shown extraordinary productivity through its integrated research programs and shared resources. The primary team includes investigators from Massachusetts Institute of Technology (MIT), Harvard Medical School (HMS), Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) and Harvard Faculty of Arts and Sciences (FAS). The CCNE thus effectively bridges programs in basic sciences at two Universities (MIT and Harvard) and clinical programs at leading Hospitals (MGH and BWH). The program will continue to be headed up by Dr. Robert Langer and Dr. Ralph Weissleder as Co-Pls. Dr. Langer is Institute Professor at MIT and member of the Koch Institute for Integrative Cancer Research at MIT (Kl). Dr. Weissleder is a Professor at Harvard Medical School, the Director of the Center for Systems Biology at MGH, a practicing clinician at MGH and a member of the Dana Farber Harvard Cancer Center. Public Health Relevance: With recent advances in nanotechnology and the introduction of some new nanomaterials into clinical trials, a myriad of opportunities are available to advance medical science and disease treatment. The translational goal is now to better control and manipulate emerging new materials by precisely configuring molecular structures, adding biological functionalities, decreasing or eliminating toxicities, and creating supramolecular

U54 应用程序的总体目标是支持由化学家、工程师、生物学家、材料科学家和临床医生组成的高度多学科团队开发和快速转化新的纳米技术，以更好地在临床诊断和治疗癌症。该团队于 2004 年成立了癌症纳米技术卓越中心 (CCNE)，在过去 5 年中通过其综合研究项目和共享资源展现了非凡的生产力。主要团队包括来自麻省理工学院 (MIT)、哈佛医学院 (HMS)、麻省总医院 (MGH) 和布莱根妇女医院 (BWH) 以及哈佛文理学院 (FAS) 的研究人员。因此，CCNE 有效地连接了两所大学（麻省理工学院和哈佛大学）的基础科学项目和领先医院（麻省总医院和 BWH）的临床项目。该项目将继续由 Robert Langer 博士和 Ralph Weissleder 博士作为联合领导。 Langer 博士是麻省理工学院的研究所教授，也是麻省理工学院（吉隆坡）科赫综合癌症研究所的成员。 Weissleder 博士是哈佛医学院教授、麻省总医院系统生物学中心主任、麻省总医院执业临床医生以及达纳法伯哈佛癌症中心成员。 公共健康相关性：随着纳米技术的最新进展以及一些新型纳米材料引入临床试验，为推进医学科学和疾病治疗提供了无数机会。现在的转化目标是通过精确配置分子结构、添加生物功能、减少或消除毒性以及创建超分子来更好地控制和操纵新兴新材料。